103 results match your criteria: "University of Tunis El Manar and Genomics Platform[Affiliation]"
Malays Fam Physician
November 2024
MD, PhD, Neurology Dpt., Neurology & Neurophysiology Center, Vienna, Austria. Email:
Neurosciences (Riyadh)
October 2024
College of Medicine, Imam Mohammad Ibn Saud Islamic University, Riyadh, Kingdom of Saudi Arabia.
Neurosciences (Riyadh)
October 2024
Department of Physical Medicine and Rehabilitation, Physical Medicine and Rehabilitation Hospital, Kuwait.
Neurosciences (Riyadh)
May 2024
Neurology & Neurophysiology Center, Vienna, Austria.
Pril (Makedon Akad Nauk Umet Odd Med Nauki)
March 2024
University of Tunis El Manar and Genomics Platform, Pasteur Institute of Tunis, Tunisia.
Cardiol Young
April 2024
University of Tunis El Manar and Genomics Platform, Pasteur Institute of Tunis, Tunis, Tunisia.
J Coll Physicians Surg Pak
April 2023
Department of Genetics, University of Tunis El Manar and Genomics Platform, Pasteur Institute of Tunis, Tunis, Tunisia.
Null.
View Article and Find Full Text PDFNeurol Neurochir Pol
May 2023
Neurology and Neurophysiology Centre, Vienna, Austria.
Neurohospitalist
October 2022
Pasteur Institute of Tunis, University of Tunis El Manar and Genomics Platform, Tunisia.
Egypt J Neurol Psychiatr Neurosurg
December 2021
University of Tunis El Manar and Genomics Platform, Pasteur Institute of Tunis, Tunis, Tunisia.
There is accumulating evidence that SARS-CoV-2 vaccinations can be complicated by venous sinus thrombosis (VST). This review aimed at summarising and discussing previous and recent advances regarding the diagnosis, pathogenesis, treatment, and outcome of post-SARS-CoV-2 vaccination VST. At least 308 patients with post-SARS-CoV-2 vaccination VST have been reported as per the end of July 2021.
View Article and Find Full Text PDFEgypt J Neurol Psychiatr Neurosurg
September 2021
Klinik Landstrasse, Messerli Institute, Postfach 20, 1180 Vienna, Austria.
Sinus venous thrombosis (SVT) is an increasingly recognised complication of not only SARS-CoV-2 infections, but also of SARS-CoV-2 vaccinations. SVT is attributed to hypercoagulability, a common complication of COVID-19, disregarding the severity of the infection. Hypercoagulability in COVID-19 is explained by direct activation of platelets, enhancing coagulation, by direct infection and indirect activation of endothelial cells by SARS-CoV-2, shifting endothelial cells from an anti-thrombotic to a pro-thrombotic state, by direct activation of complement pathways, promoting thrombin generation, or by immune thrombocytopenia, which also generates a thrombogenic state.
View Article and Find Full Text PDFBasic Clin Neurosci
January 2020
University of Tunis El Manar and Genomics Platform, Pasteur Institute of Tunis, Tunisia.
J Anaesthesiol Clin Pharmacol
January 2019
University of Tunis El Manar and Genomics Platform, Pasteur Institute of Tunis, Tunisia.
J Pediatr Neurosci
September 2019
Pasteur Institute of Tunis, University of Tunis El Manar and Genomics Platform, Tunis, Tunisia.
J Coll Physicians Surg Pak
August 2019
University of Tunis El Manar and Genomics Platform, Pasteur Institute of Tunis, Tunisia.
Asian J Psychiatr
March 2019
Krankenanstalt Rudolfstiftung, Vienna, Austria; University of Tunis El Manar and Genomics Platform, Pasteur Institute of Tunis, Tunisia.
Doc Ophthalmol
June 2019
Pasteur Institute of Tunis, University of Tunis El Manar and Genomics Platform, Tunis, Tunisia.
Arq Neuropsiquiatr
February 2019
University of Tunis El Manar and Genomics Platform, Pasteur Institute of Tunis, Tunisia.
J Neurol Sci
February 2019
University of Tunis El Manar and Genomics Platform, Pasteur Institute of Tunis, Tunisia.
J Clin Neurosci
March 2019
University of Tunis El Manar and Genomics Platform, Pasteur Institute of Tunis, Tunisia.
Mol Genet Metab Rep
December 2018
University of Tunis El Manar and Genomics Platform, Pasteur Institute of Tunis, Tunisia.
Indian J Pediatr
February 2019
University of Tunis El Manar and Genomics Platform, Pasteur Institute of Tunis, Tunis, Tunisia.
Herz
June 2020
Pasteur Institute of Tunis, University of Tunis El Manar and Genomics Platform, Tunis, Tunisia.
Objectives: Little is known about cardiac involvement in m.3243A>G variant carriers. Thus, this study aimed to assess type and frequency of cardiac disease in symptomatic and asymptomatic m.
View Article and Find Full Text PDFBrain Dev
January 2019
University of Tunis El Manar and Genomics Platform, Pasteur Institute of Tunis, Tunisia.
Mol Genet Metab Rep
September 2018
University of Tunis El Manar and Genomics Platform, Pasteur Institute of Tunis, Tunisia.